Share on StockTwits

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) issued an update on its FY14 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.51-0.57 for the period, compared to the Thomson Reuters consensus estimate of $0.40, Analyst Ratings Network reports. The company issued revenue guidance of $130-135 million, compared to the consensus revenue estimate of $130.12 million.

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) traded up 0.60% during mid-day trading on Monday, hitting $5.04. 187,520 shares of the company’s stock traded hands. SciClone Pharmaceuticals Inc. has a one year low of $4.24 and a one year high of $6.01. The stock’s 50-day moving average is $5.09 and its 200-day moving average is $4.86. The company has a market cap of $259.5 million and a price-to-earnings ratio of 25.18.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its earnings results on Monday, August 11th. The company reported $0.20 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.10. The company had revenue of $32.50 million for the quarter, compared to the consensus estimate of $33.40 million. During the same quarter last year, the company posted ($0.04) earnings per share. SciClone Pharmaceuticals’s revenue was up 10.9% compared to the same quarter last year. On average, analysts predict that SciClone Pharmaceuticals Inc. will post $0.40 earnings per share for the current fiscal year.

SciClone Pharmaceuticals, Inc (NASDAQ:SCLN) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.